In hepatocellular carcinoma (HCC), SFRP genes are frequently inactivated, and this is also observed in premalignancy, with SFRP2 predicted to be inactivated by promoter hypermethylation in 33% and 42% of HBV-driven and HCV-driven hepatitis samples, respectively [95]. The gene discussed is SFRP2; the disease is hepatocellular carcinoma.